Article
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.
Blood - 3 May 2018
Chen Jiaji G, Liu Xia, Munshi Manit, Xu Lian, Tsakmaklis Nicholas, Demos Maria G, Kofides Amanda, Guerrera Maria Luisa, Chan Gloria G, Patterson Christopher J, Meid Kirsten, Gustine Joshua, Dubeau Toni, Severns Patricia, Castillo Jorge J, Hunter Zachary R, Wang Jinhua, Buhrlage Sara J, Gray Nathanael S, Treon Steven P, Yang Guang
Abstract excerpt
Acquired ibrutinib resistance due to BTKCys481 mutations occurs in B-cell malignancies, including those with MYD88 mutations. BTKCys481 mutations are usually subclonal, and their relevance to clinical progression remains unclear. Moreover, the signaling pathways that promote ibrutinib resistance remain to be clarified. We therefore engineered BTKCys481Ser and BTKWT expressing MYD88-mutated Waldenström...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.